Retatrutide vs Tirzepatide: research-use price per mg, identity and FDA status (2026)
Retatrutide and Tirzepatide are different research compounds, not substitutes for each other: Retatrutide is a single compound (C221H342N46O68); Tirzepatide is a single compound (C225H348N48O68). Lowest current research-use listings: Retatrutide 30mg from $229.99 ($7.67/mg) at LA Peptides; Tirzepatide 30mg from $149.99 ($5.00/mg) at Nova Peptide Supply. Retatrutide has no Drugs@FDA application; Tirzepatide shares its active ingredient with an FDA-approved prescription medicine.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
Retatrutide vs Tirzepatide: current prices and packages
| Compared property | Retatrutide | Tirzepatide |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Compared package | 30mg · Vial | 30mg · Vial |
| Lowest current price | $229.99 at LA Peptides, checked Oct 31, 2026 | $149.99 at Nova Peptide Supply, checked Oct 31, 2026 |
| Price per labelled mg | $7.67/mg | $5.00/mg |
| Package sizes | 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 48mg, 50mg, 60mg | 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 100mg |
| Vendors with current prices | 2 (4 tracked) | 3 (5 tracked) |
| Form at this package | Vial | Vial |
| Stock | In stock | In stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Retatrutide | Tirzepatide |
|---|---|---|
| Molecular formula | C221H342N46O68 | C225H348N48O68 |
| Molecular weight | 4731 g/mol | 4813 g/mol |
| Sequence | — | — |
| CAS Registry Number | — | — |
| Registered clinical trials | 34 (11 active) · Phase 3: 14, Phase 2: 4, Phase 1: 15 | 38 (38 active) · Phase 4: 9, Phase 3: 6, Phase 2: 14 |
| Human intervention studies | 7 | 7 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | FDA-approved prescription medicine with this active ingredient: Mounjaro and Zepbound (NDA 215866 and NDA 217806; checked October 7, 2026)MarketedMOUNJARO · NDA 215866 · 2022ZEPBOUND · NDA 217806 · 2023Research listings are not these medicines. |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Retatrutide
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024
Tirzepatide
- Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine, 2025
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine, 2025
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine, 2024
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
Retatrutide
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.
$229.99 · 30mg · $7.67/mg · LA Peptides
View at LA Peptides, Retatrutide 30mg, opens in a new tabPeptideTech does not sell or fulfill products. Some outgoing links can earn a commission, which does not determine price order. How we rankRetatrutide prices →Price history →Tirzepatide
Tirzepatide acts at GIP and GLP-1 receptors and is the active substance in the EU-authorized prescription medicine Mounjaro. Its medicinal-product assessment is separate from a supplier’s research catalogue listing.
$149.99 · 30mg · $5.00/mg · Nova Peptide Supply
View at Nova Peptide Supply, Tirzepatide 30mg, opens in a new tabPeptideTech does not sell or fulfill products. Some outgoing links can earn a commission, which does not determine price order. How we rankTirzepatide prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →